Navigation Links
Regulus Demonstrates Initial Progress in microRNA Biomarkers MS Collaboration and Receives Milestone Payment from Biogen Idec
Date:11/20/2013

biomarkers may be used to select optimal patient segments in clinical trials, to develop companion diagnostics, and to monitor disease progression or relapse. 

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company. Regulus has a well-balanced microRNA therapeutic pipeline entering clinical development, an emerging microRNA biomarkers platform to support its therapeutic programs, and a rich intellectual property estate to retain its leadership in the microRNA field. Regulus intends to focus its proprietary efforts on developing microRNA therapeutics for oncology indications and orphan diseases and is currently advancing several programs toward clinical development in oncology, fibrosis and metabolic diseases. Regulus is also developing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122, for the treatment of chronic hepatitis C virus infection. Regulus' commitment to innovation and its leadership in the microRNA field have enabled the formation of strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi. In addition, Regulus has formed a research collaboration with Biogen Idec around its emerging microRNA biomarkers platform. 

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus' expectations regarding future
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology news :

1. Study demonstrates cells can acquire new functions through transcriptional regulatory network
2. New study demonstrates the role of urban greenery in CO2 exchange
3. WALTHAM® demonstrates commitment to scientific dialogue and exchange at international human animal interaction conference
4. Published clinical trial demonstrates efficacy of Sea-Band® for migraine-related nausea
5. University of Toronto study demonstrates impact of adversity on early life development
6. UT Arlington physics team demonstrates new power generation technique
7. First-in-man study demonstrates the therapeutic effect of RNAi gene silencing in cancer treatment
8. Genetic study of house dust mites demonstrates reversible evolution
9. Rotavirus vaccine developed in India demonstrates strong efficacy
10. Fingerprint Cards (FPC) Demonstrates Fingerprint Biometric Touch Sensor for Microsoft Windows 8.1
11. Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... to their offering. One major trend ... biometric systems. Multimodal biometric systems utilize more than one ...
(Date:12/10/2014)... Baptist Medical Center today announced plans for a new medical ... $50 million capital project is part of a larger capital ... The medical education building will be located in the ... 525@vine in Wake Forest Innovation Quarter. Construction will begin immediately ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... Huntington,s disease, a mutated protein in the body becomes toxic ... small region adjacent to the mutated segment plays a major ... the National Institutes of Health show that very slight changes ... mice. Researchers do not fully understand why the protein ...
... the atomic structure of new anti-cancer agents has enabled a ... capable of halting a common type of drug-resistant lung cancer. ... 24/31 issue of the journal Nature , the researchers ... to the drugs Iressa and Tarceva were stymied by a ...
... Microbiology has awarded one of its international professorships to ... department at Kansas State University. The society has ... will be a visiting professor at the Universidad Nacional ... his Fusarium Laboratory Workshop in March 2010. The ...
Cached Biology News:Small changes in protein chemistry play large role in Huntington's disease 2Small changes in protein chemistry play large role in Huntington's disease 3Research yields new agent for some drug-resistant non-small cell lung cancers 2Research yields new agent for some drug-resistant non-small cell lung cancers 3
(Date:1/23/2015)... Biofertilizers stimulate microbial activities in soil. These microorganisms ... the activities in the soil or in the rhizosphere. ... stress on reducing environmental pollution and on reducing the ... segments the bio fertilizers market with analysis and forecasting ...
(Date:1/23/2015)... 2015 Portal Solutions , a technology ... Microsoft Office 365 and SharePoint platforms , today announces ... for being one of the region’s fastest-growing mid-sized companies based ... , “To be recognized a second year in a ...
(Date:1/22/2015)... January 22, 2015 Shimadzu Scientific ... UV-1280 multipurpose UV-visible spectrophotometer. Offering wavelength scanning from ... is ideal for applications in a variety of ... , The user-friendly UV-1280 enables intuitive operation, while ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 GEA Niro ... table top laboratory homogenizer, the PandaPLUS 2000, which is ... nanoemulsions , and cell disruption . This compact ... products, fruit juices, liquid food, food additives and ingredients ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 2Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 3Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2
... 7 Biocept, Inc. ("Biocept"), an emerging leader in biotechnology, ... "We are pleased to welcome Bruce to ... we move into our next stage of development," said Stephen ... been a practicing Certified Public Accountant since 1986.  He is ...
... that a new market research report is available in ... R&D: Technology and Market 2010-2025 ... – how will biobanking develop and contribute to healthcare? ... you want to know the prospects for biobanking in ...
... Pharmaceutical Inc. (Nasdaq: BMRN ) ... Officer of BioMarin, will host a conference ... at 5:00 p.m. ET to discuss third ... Number:  866.202.3048International Dial-in Number:  617.213.8843Participant Code: 60493555Replay ...
Cached Biology Technology:Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 2Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 3Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 4Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 5Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 6Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 7Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 8Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 9Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 10Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 11BioMarin to Host Third Quarter 2010 Financial Results Conference Call and Webcast on Thursday, October 28 at 5:00 p.m. ET 2
ROCK-1 (cleaved) Monoclonal Ab 100 ug purified mouse monoclonal antibody. Clone# 12M03. Reacts with human. Tested in Western blot analysis....
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
Mouse monoclonal [CAT-1] to Chloramphenicol Acetyltransferase ( Abpromise for all tested applications)....
... are designed for use with the ProQuest ... MaV203 contains deletions in the endogenous GAL4 ... two-hybrid systems. The strain also has leu2 ... bait and prey vectors. MaV203 contains three ...
Biology Products: